Literature DB >> 23657855

Gender-specific role of HDAC11 in kidney ischemia- and reperfusion-induced PAI-1 expression and injury.

Jee In Kim1, Kyong-Jin Jung, Hee-Seong Jang, Kwon Moo Park.   

Abstract

Male gender and the male hormone testosterone increase susceptibility to kidney ischemia and reperfusion (I/R) injury, which is associated with inflammatory responses. Possible involvement of histone deacetylase (HDAC) in inflammatory responses has been suggested. We investigated the gender-specific role of HDACs in plasminogen activator inhibitor type-1 (PAI-1) expression and I/R injury. PAI-1 inhibition protected the kidney from I/R-induced inflammation and functional loss. Among HDACs, only HDAC11 negatively regulated PAI-1 expression in I/R-subjected kidney gender specifically and lipopolysaccharide (LPS)-stimulated mouse monocytes/macrophages. HDAC11 gene silencing increased PAI-1 expression. Chromatin immunoprecipitation assay confirmed binding of HDAC11 to the promoter region of PAI-1 and then release by I/R insult or LPS treatment. I/R-induced HDAC11 release was inhibited by orchiectomy and reversed by dihydrotestosterone treatment. Release of HDAC11 increased acetylation of histone H3. In conclusion, male gender and male hormones accelerate I/R-induced decreases in expression and binding of HDAC11, resulting in an increase in PAI-1 expression. These data provide important insight into gender dimorphism offering HDAC11 as a novel target for I/R injury.

Entities:  

Keywords:  HDAC11; PAI-1; gender dimorphism; kidney ischemia and reperfusion

Mesh:

Substances:

Year:  2013        PMID: 23657855     DOI: 10.1152/ajprenal.00015.2013

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  16 in total

1.  Impaired cytokine expression, neutrophil infiltration and bacterial clearance in response to urinary tract infection in diabetic mice.

Authors:  Ahmet Ozer; Cengiz Z Altuntas; Fuat Bicer; Kenan Izgi; Scott J Hultgren; Guiming Liu; Firouz Daneshgari
Journal:  Pathog Dis       Date:  2015-02-05       Impact factor: 3.166

2.  Beware the low HDAC11: males at risk for ischemic kidney injury.

Authors:  Michal Mrug; Paul W Sanders
Journal:  Am J Physiol Renal Physiol       Date:  2013-07-24

Review 3.  Renoprotective approaches and strategies in acute kidney injury.

Authors:  Yuan Yang; Meifang Song; Yu Liu; Hong Liu; Lin Sun; Youming Peng; Fuyou Liu; Manjeri A Venkatachalam; Zheng Dong
Journal:  Pharmacol Ther       Date:  2016-04-22       Impact factor: 12.310

Review 4.  Epigenetics in Kidney Transplantation: Current Evidence, Predictions, and Future Research Directions.

Authors:  Valeria R Mas; Thu H Le; Daniel G Maluf
Journal:  Transplantation       Date:  2016-01       Impact factor: 4.939

Review 5.  Epigenetics in kidney diseases.

Authors:  Hao Ding; Lu Zhang; Qian Yang; Xiaoqin Zhang; Xiaogang Li
Journal:  Adv Clin Chem       Date:  2020-10-21       Impact factor: 6.303

Review 6.  Application of Histone Deacetylase Inhibitors in Renal Interstitial Fibrosis.

Authors:  Ling Nie; Yong Liu; Bo Zhang; Jinghong Zhao
Journal:  Kidney Dis (Basel)       Date:  2020-03-26

7.  Hydroxytyrosol Acetate Inhibits Vascular Endothelial Cell Pyroptosis via the HDAC11 Signaling Pathway in Atherosclerosis.

Authors:  Feng Yao; Zhen Jin; Xiaohan Lv; Zihan Zheng; Hongqian Gao; Ying Deng; Yizhen Liu; Lifang Chen; Weirong Wang; Jianyu He; Jianli Gu; Rong Lin
Journal:  Front Pharmacol       Date:  2021-04-23       Impact factor: 5.810

Review 8.  Treatment of chronic kidney diseases with histone deacetylase inhibitors.

Authors:  Na Liu; Shougang Zhuang
Journal:  Front Physiol       Date:  2015-04-28       Impact factor: 4.566

Review 9.  The Role and Mechanism of Histone Deacetylases in Acute Kidney Injury.

Authors:  Xun Zhou; Hui Chen; Yingfeng Shi; Xiaoyan Ma; Shougang Zhuang; Na Liu
Journal:  Front Pharmacol       Date:  2021-06-16       Impact factor: 5.810

10.  TEL2 suppresses metastasis by down-regulating SERPINE1 in nasopharyngeal carcinoma.

Authors:  Yi Sang; Ming-Yuan Chen; Donghua Luo; Ru-Hua Zhang; Li Wang; Mei Li; Rongzhen Luo; Chao-Nan Qian; Jian-Yong Shao; Yi-Xin Zeng; Tiebang Kang
Journal:  Oncotarget       Date:  2015-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.